Results 31 to 40 of about 14,398,598 (290)

Ligand-based targeting of c-kit using engineered γδ T cells as a strategy for treating acute myeloid leukemia

Frontiers in Immunology, 2023
The application of immunotherapies such as chimeric antigen receptor (CAR) T therapy or bi-specific T cell engager (BiTE) therapy to manage myeloid malignancies has proven more challenging than for B-cell malignancies. This is attributed to a shortage of
Gianna M. Branella, Gianna M. Branella, Gianna M. Branella, Jasmine Y. Lee, Jasmine Y. Lee, Jasmine Y. Lee, Jennifer Okalova, Jennifer Okalova, Jennifer Okalova, Kiran K. Parwani, Kiran K. Parwani, Kiran K. Parwani, Jordan S. Alexander, Jordan S. Alexander, Raquel F. Arthuzo, Raquel F. Arthuzo, Raquel F. Arthuzo, Andrew Fedanov, Andrew Fedanov, Bing Yu, David McCarty, Harrison C. Brown, Shanmuganathan Chandrakasan, Shanmuganathan Chandrakasan, Brian G. Petrich, Christopher B. Doering, Christopher B. Doering, Christopher B. Doering, H. Trent Spencer, H. Trent Spencer, H. Trent Spencer   +30 more
doaj   +1 more source

Engager T Cells: A New Class of Antigen-specific T Cells That Redirect Bystander T Cells [PDF]

Molecular Therapy, 2015
Adoptive immunotherapy with antigen-specific T cells has shown promise for the treatment of malignancies. However, infused T cells are unable to redirect resident T cells, limiting potential benefit. While the infusion of bispecific T-cell engagers can redirect resident T cells to tumors, these molecules have a short half-life, and do not self amplify.
Iwahori, Kota, Kakarla, Sunitha, Velasquez, Mireya P, Yu, Feng, Yi, Zongzhen, Gerken, Claudia, Song, Xiao-Tong, Gottschalk, Stephen   +7 more
openaire   +2 more sources

Conformation-selective rather than avidity-based binding to tumor associated antigen derived peptide-MHC enables targeting of WT1-pMHC low expressing cancer cells by anti-WT1-pMHC/CD3 T cell engagers

Frontiers in Immunology, 2023
T cell engagers, a category of T cell-retargeting immunotherapy, are rapidly transforming clinical cancer care. However, the lack of tumor-specific targets poses a significant roadblock for broad adaptation of this therapeutic modality in many ...
Even Walseng, Bo Wang, Chunning Yang, Pooja Patel, Chihao Zhao, Hanzhi Zhang, Peng Zhao, Yariv Mazor   +7 more
doaj   +1 more source

CD3‐T‐cell‐engager (TCE) therapies to overcome solid tumors: Beyond BiTEs

MedComm – Biomaterials and Applications, 2022
CD3‐T‐cell‐engager (TCE) therapies, such as bispecific T‐cell engagers (BiTEs), have achieved extraordinary success in treating hematological malignancies and have shown therapeutic effects comparable with those of chimeric antigen receptor (CAR)‐T ...
Jiali Zhang, Qianqian Guo, Quan Wang, Yourong Duan   +3 more
doaj   +1 more source

Programmable half-life and anti-tumour effects of bispecific T-cell engager-albumin fusions with tuned FcRn affinity

Communications Biology, 2021
Mandrup et al. describe a panel of recombinant albumin fusions, engineered with different affinities to the human neonatal Fc receptor to program the half-life extension of a bispecific (EGFR/CD3) T-cell engager.
Ole A. Mandrup, Sui Ching Ong, Simon Lykkemark, Anders Dinesen, Imke Rudnik-Jansen, Niels Frederik Dagnæs-Hansen, Jan Terje Andersen, Luis Alvarez-Vallina, Kenneth A. Howard   +8 more
doaj   +1 more source

Designing Cancer Immunotherapies That Engage T Cells and NK Cells

Annual Review of Immunology, 2023
T cells and natural killer (NK) cells have complementary roles in tumor immunity, and dual T cell and NK cell attack thus offers opportunities to deepen the impact of immunotherapy. Recent work has also shown that NK cells play an important role in recruiting dendritic cells to tumors and thus enhance induction of CD8 T cell responses, while IL-2 ...
Oleksandr, Kyrysyuk, Kai W, Wucherpfennig   +1 more
openaire   +2 more sources

Additional file 1 of Nanobody-based trispecific T cell engager (Nb-TriTE) enhances therapeutic efficacy by overcoming tumor-mediated immunosuppression

, 2023
Additional file 1. Nanobody-based trispecific T cell engager (Nb-TriTE) enhances therapeutic efficacy by overcoming tumor-mediated ...
Xiaomei Yang (66683), Xuan Wang (55634), Xiaobing Jiang (3278892), Xiaoqiong Hou (17486588), Zhuoran Tang (17273953), Xianing Huang (3121944), Wei Shi (68167), Xiaoling Lu (671363), Shenxia Xie (17486582), Shuyang Sun (282957), Ziqiang Ding (17486579), Fengzhen Mo (17486585), Aiqun Liu (749999)   +12 more
core   +1 more source

T Cell-Activating Mesenchymal Stem Cells as a Biotherapeutic for HCC

Molecular Therapy: Oncolytics, 2017
The outcome for advanced stage hepatocellular carcinoma (HCC) remains poor, highlighting the need for novel therapies. Genetically modified mesenchymal stem cells (MSCs) are actively being explored as cancer therapeutics due to their inherent ability to ...
Arpad Szoor, Abishek Vaidya, Mireya Paulina Velasquez, Zhuyong Mei, Daniel L. Galvan, David Torres, Adrian Gee, Andras Heczey, Stephen Gottschalk   +8 more
doaj   +1 more source

Progress of research on PD-1/PD-L1 in leukemia

Frontiers in Immunology, 2023
Leukemia cells prevent immune system from clearing tumor cells by inducing the immunosuppression of the bone marrow (BM) microenvironment. In recent years, further understanding of the BM microenvironment and immune landscape of leukemia has resulted in ...
Huizhen Cao, Tianyu Wu, Xue Zhou, Shuyang Xie, Hongfang Sun, Yunxiao Sun, Youjie Li   +6 more
doaj   +1 more source

Evaluation of an anti-CD3 VHH and construction of an anti-CD3/anti-EGFR bispecific tandem VHH as a cancer cell targeting drug construct

Biochemistry and Biophysics Reports
Recently, the development of T-cell engager cancer therapeutics, consisting of anticancer and anti-T-cell antibody parts to engage the T-cell to the cancer site, has gained interest.
Takuya Asanuma, Peiwei Ding, Yuki Kato, Takeshi Nakanishi, Ryutaro Asano, Koki Makabe   +5 more
doaj   +1 more source